Beam Therapeutics (NASDAQ:BEAM), Inc. is a biotechnology company pioneering precision genetic medicines through base editing, a next-generation genome editing approach that enables targeted, permanent correction of single nucleotides in DNA without introducing double-strand breaks. The company leverages proprietary base editing platforms to develop treatments for monogenic diseases, immuno-oncology, and other therapeutic areas where precise DNA modifications can deliver durable benefits. Beam’s core technology builds on research from the Broad Institute and Harvard University, positioning the company at the forefront of the gene editing field.
The company’s research pipeline includes several in vivo and ex vivo programs designed to address rare blood disorders and other genetic diseases. Lead programs focus on conditions such as sickle cell disease and beta-thalassemia, with preclinical and early clinical studies evaluating the safety and efficacy of base editing in hematopoietic stem cells. In addition to hematology, Beam is advancing programs targeting lipid disorders through PCSK9 base editing and exploring novel immuno-oncology approaches by modifying immune cell function to enhance anti-tumor activity.
Beam Therapeutics was founded in 2017 and is headquartered in Cambridge, Massachusetts, with research facilities that support both discovery and early development activities. The company has established collaborations and strategic partnerships with leading pharmaceutical organizations to expand its research capabilities and accelerate the translation of its base editing technology. Beam’s team combines expertise in molecular biology, protein engineering, and translational medicine to drive innovation from bench to bedside.
Leadership at Beam includes co-founder Dr. David R. Liu, whose pioneering work in base editing laid the scientific foundation for the company, alongside an experienced executive team focused on clinical development and commercialization strategy. By integrating cutting-edge science with robust translational pathways, Beam Therapeutics aims to deliver transformative therapies that address genetic diseases with high unmet medical need.
